Apogee Therapeutics (APGE) EBT (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of EBT data on file, last reported at -$74.0 million in Q1 2026.

• On a quarterly basis, EBT fell 33.98% year-over-year to -$74.0 million in Q1 2026; TTM through Mar 2026 was -$274.3 million, a 33.64% decrease from a year earlier, with the FY2025 full-year figure at -$255.6 million, down 40.32% from the prior year.
• EBT for Q1 2026 stood at -$74.0 million, down from -$69.3 million in the prior quarter.
• Over the last five years, EBT for APGE reached as high as -$1.8 million in Q2 2022 and fell as low as -$74.0 million in Q1 2026.
• Historically, EBT has averaged -$41.3 million across 5 years, with a median of -$41.4 million in 2024.
• Across the five-year window, EBT slumped 939.92% in 2023 and slipped 3.16% in 2025, its largest moves.
• Year by year, EBT stood at -$20.8 million in 2022, then sank by 197.92% to -$61.9 million in 2023, then slipped by 8.54% to -$67.2 million in 2024, then slipped by 3.16% to -$69.3 million in 2025, then retreated by 6.79% to -$74.0 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$74.0 million in Q1 2026, -$69.3 million in Q4 2025, and -$65.0 million in Q3 2025.